Aktienanalyse zu TScan Therapeutics Inc (TCRX)TCRXTScan Therapeutics Inc

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company is advancing two therapeutics candidates through IND-enabling studies to treat solid tumors using in vivo-engineered TCR-T cells. In addition, the Company is seeking partnerships for its hematologic malignancies and autoimmune programs. Its construct consists of two proprietary components: dual-targeting antibodies that direct the virus to cytotoxic and helper T-cells and mediate T cell activation, and a non-targeting fusogen that mediates entry exclusively to T-cells. Its hematology program is designed to address patients who are diagnosed with hematologic malignancies and can benefit from undergoing allogeneic transplantation. Its TSC-102-A01 and TSC-102-A03 are allogeneic, donor-derived TCR-T therapy candidates targeting epitopes derived from CD45. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

TScan Therapeutics Inc (TCRX) is not a good buy right now due to its current price of $0.19, which is significantly below its 52-week high of $1.47 and reflects an 81.73% year-to-date decline. The RSI of 43.9 indicates a lack of momentum, and the recent downgrade by analysts to a price target of $1 raises concerns about future profitability and cash runway. The primary risk is the company's negative earnings trend, with a net income loss of $30.4 million reported in Q2 2026, suggesting ongoing financial challenges.